Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
2.340
+0.100 (4.46%)
At close: Feb 6, 2026, 4:00 PM EST
2.440
+0.100 (4.27%)
After-hours: Feb 6, 2026, 7:06 PM EST
Veru Inc. Employees
Veru Inc. had 20 employees as of September 30, 2025. The number of employees decreased by 190 or -90.48% compared to the previous year.
Employees
20
Change (1Y)
-190
Growth (1Y)
-90.48%
Revenue / Employee
n/a
Profits / Employee
-$1,136,314
Market Cap
37.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 20 | -190 | -90.48% | 20 | 0 |
| Sep 30, 2024 | 210 | 21 | 11.11% | 210 | 0 |
| Sep 30, 2023 | 189 | -44 | -18.88% | 189 | 0 |
| Sep 30, 2022 | 233 | -19 | -7.54% | 233 | 0 |
| Sep 30, 2021 | 252 | -87 | -25.66% | 252 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Generation Bio Co. | 115 |
| Xilio Therapeutics | 64 |
| NextCure | 43 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| TuHURA Biosciences | 19 |
VERU News
- 3 days ago - Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - GlobeNewsWire
- 7 weeks ago - Veru Inc. (VERU) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress - GlobeNewsWire
- 2 months ago - Veru to Report Fiscal Year 2025 Financial Results on December 17th - GlobeNewsWire
- 3 months ago - Veru to Present Two Abstracts at ObesityWeek 2025 - GlobeNewsWire
- 3 months ago - Veru Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity - GlobeNewsWire
- 6 months ago - Veru Inc. (VERU) Q3 2025 Earnings Call Transcript - Seeking Alpha